Multiple Myeloma, Relapse Multiple Myeloma
Conditions
Keywords
Multiple myeloma, Relapse, Dexamethasone, Isatuximab, Pomalidomide, Carfilzomib
Brief summary
Patients with relapsed/refractory symptomatic multiple myeloma who meet all inclusion criteria, will be randomized 1:1 to receive either standard of care chemotherapy (IKEMA or ICARIA) and dexamethasone until disease progression (dexamethasone arm, arm A) or standard of care chemotherapy (IKEMA or ICARIA) and dexamethasone with dexamethasone discontinuation from the 3rd cycle of treatment (after 8 weeks) (dexamethasone-free arm, arm B). In most centers, IKEMA and ICARIA schema can be adapted according to the standard of care in each center Choice between the ICARIA and IKEMA schema is at the discretion of the investigator, in compliance with each drug's SmPC, but must be performed before randomisation for the purpose of stratification.
Detailed description
Patients with relapsed/refractory symptomatic multiple myeloma who meet all inclusion criteria, will be randomized 1:1 to receive either standard of care chemotherapy (IKEMA or ICARIA) and dexamethasone until disease progression (dexamethasone arm, arm A) or standard of care chemotherapy (IKEMA or ICARIA) and dexamethasone with dexamethasone discontinuation from the 3rd cycle of treatment (after 8 weeks) (dexamethasone-free arm, arm B). In most centers, IKEMA and ICARIA schema are as follow, but can be adapted according to the standard of care in each center Choice between the ICARIA and IKEMA schema is at the discretion of the investigator, in compliance with each drug's SmPC, but must be performed before randomisation for the purpose of stratification. 1. ICARIA schema: * dexamethasone: 40mg (20mg for ≥75yr) on day 1, 8, 15, 22 of each cycle plus * isatuximab: 10mg/kg on day 1, 8, 15, 22 in C1 subsequently on day 1, 15; plus * pomalidomide: 4mg on days 1-21 of 28-day cycle. 2. IKEMA schema: * dexamethasone: 20 mg on day 1-2, day 8-9, day 15-16 and day 22-23 of each cycle; * isatuximab: 10 mg/kg on day 1, 8, 15, 22 in C1, then Q2W; * carfilzomib: 20 mg/m² on day 1-2; 56 mg/m² day 8-9, day, 15-16 in C1; 56 mg/m² on day 1-2, day 8-9, day 15-16 all subsequent cycles. In the dexamethasone arm (standard of care): Dexamethasone: will be given on each cycle In the dexamethasone-free arm (experimental arm): Dexamethasone: will be only given on cycle 1 and cycle 2 Supportive care: will be administered according to each participating center's usual practice, in both arms The aim of the current protocol is to investigate whether administration of dexamethasone for a very limited period (2 cycles) combined with standard treatment for relapsed/refractory MM is not inferior to the continuous administration of the combination until disease progression. In this study some patients may have a similar OS while receiving a shorter duration of dexamethasone treatment. This study may allow delivery of a shorter duration of dexamethasone for the treatment of relapsed MM. The foreseeable risks are those of an earlier relapse in patients receiving a short duration of dexamethasone (8 weeks) compared to the situation where they would have received the dexamethasone until disease progression.
Interventions
DRUGDexamethasone
ICARIA schema : 40mg (20mg for ≥75yr) on day 1, 8, 15, 22 of each cycle plus IKEMA schema : 20 mg on day 1-2, day 8-9, day 15-16 and day 22-23 of each cycle For subjects older than 75 years or underweight (BMI \<18.5), the dexamethasone dose may be administered at a total dose of 20 mg weekly. In both schema (ICARIA or IKEMA), dexamethasone will be administrated up to 2 cycle (Arm 1) or until disease progression (Arm2)
Sponsors
Assistance Publique - Hôpitaux de Paris
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Adult patients (≥18 years old) 2. Documented MM in relapse according to standard criteria. 3. All patients must have received between 1 to 3 prior therapies for MM (a prior therapy is defined as 2 or more cycles of therapy given as a MM treatment plan) * Eligible for one of the following antibody-based approved combinations: 1. ICARIA schema: isatuximab, pomalidomide and dexamethasone. 2. IKEMA schema: isatuximab, carfilzomib and dexamethasone 4. Subject must have achieved a response (PR or better) to the prior regimen. 5. ECOG Performance Status score of 0, 1, or 2. 6. For subjects experiencing toxicities resulting from previous therapy (including peripheral neuropathy), the toxicities must have been resolved or stabilized. 7. Signed informed consent
Exclusion criteria
1. Contraindications to investigational medicinal products or auxiliary medicinal product 2. Evidence of refractoriness or intolerance to anti-CD38 monoclonal antibodies. 3. Previous treatment according to the ICARIA schema with pomalidomide or IKEMA schema with carfilzomib 4. Allogenic hematopoietic cell transplant (HCT, regardless of timing). 5. Planned to undergo an hematopoietic cell transplant prior to progression of disease ie, these patients should not be enrolled in order to reduce disease burden prior to transplant. 6. History of malignancy (other than MM) within 3 years before the date of randomization (exceptions are squamous and basal cell carcinomas of the skin, carcinoma in situ of the cervix, or malignancy that in the opinion of the Investigator is considered cured with minimal risk of recurrence within 3 years). 7. Known MM meningeal Involvement. 8. Plasma cell leukemia (\>2.0 × 109/L circulating plasma cells by standard differential) or Waldenström's macroglobulinemia or POEMS syndrome (polyneuropathy, organomegaly, endocrinopathy, monoclonal protein, and skin changes) or amyloidosis. 9. Any concurrent medical condition or disease (e.g., active systemic infection) that is likely to interfere with study procedures or results, or that, in the opinion, of the Investigator would constitute a hazard by participating in this study. 10. Uncontrolled chronic obstructive pulmonary disease (COPD) 11. Clinically significant cardiac disease. 12. Seropositive for hepatitis B with positive PCR 13. Seropositive for human immunodeficiency virus (HIV) or hepatitis C 14. Lactation 15. Participation to another interventional clinical trial 16. Inability to give written informed consent
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| overall response rate (ORR). | At the end of Cycle 6 of salvage therapy (each cycle is 28 days) | Response rate will be evaluated according to the IMWG criteria, after six 28 days cycles of salvage therapy. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| best overall response rate (ORR) | 2 years | Response rate will be evaluated according to the IMWG criteria, during or after the study treatment at the time of data cutoff. Patients will be followed every 4 weeks (with either a medical visit or only an outpatient blood test) until disease progression and then every 12 weeks until final 2 years. |
| Time To Progress (TTP) | 2 years | Time To Progress defined as the duration from the date of randomization to progressive disease, according to the IMWG criteria |
| Progression free survival (PFS) | 2 years | Progression free survival is defined as the duration from the date of randomization to either progressive disease, according to the IMWG critera or death, at 2 years after randomization. |
| Overall survival OS | 2 years | which is defined as the time between randomization and death due to any cause. Patients, who die, regardless of the cause of death, will be considered to have had an event even if they were lost to follow-up for an extended time |
| Quality of Life (QoL) | 2 years | — |
Countries
France
Contacts
Primary ContactMohamad MOHTY, PU-PH
Backup ContactFlorent MALARD, PU-PH
Outcome results
None listed